Atypical haemolytic uraemic syndrome and mutations in complement regulator genes View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-09-28

AUTHORS

Marie-Agnès Dragon-Durey, Véronique Frémeaux-Bacchi

ABSTRACT

Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) disorder characterised by the association of haemolytic anaemia, thrombocytopenia and acute renal failure. Atypical forms (non-related to shigatoxin) may be familial or sporadic, with frequent recurrences and most of them lead to end stage renal failure. During the last years, different groups have demonstrated genetic predisposition of atypical HUS involving complement components factor H (FH), CD46 [or membrane co-factor protein (MCP)] and factor I. These three proteins are involved in the regulation of the alternative pathway of the complement system. Several series have reported mutations in the FH gene (called HF1) in between 10 and 22% of atypical HUS patients. At this time, four pedigrees corresponding to 13 cases have been reported with an MCP mutation and four cases with a sporadic disease presented factor I mutation. Whereas FH mutations were reported in both familial and sporadic forms of HUS, CD46 mutations were restricted to familial HUS, and factor I mutations were only observed in cases of sporadic HUS. We speculate that the penetrance of the disease may be variable regarding the identified susceptibility factors. Recently, the analysis of single nucleotide polymorphisms in both HF1 and MCP in three large cohorts of HUS patients identified significant association between atypical HUS and HF1 and MCP particular alleles. All these results, together with the finding of anti-FH antibodies in some atypical HUS patients, strongly suggest that an abnormality in the regulation of the alternative pathway participates in the patho-physiological mechanisms of atypical HUS. The recent progress made in the determination of susceptibility factors for atypical HUS has permitted the development of new diagnostic tests and may eventually lead to new specific treatments to block the pathological process. More... »

PAGES

359-374

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2

DOI

http://dx.doi.org/10.1007/s00281-005-0003-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034722638

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16189652


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Autoantibodies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement Factor H", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement Factor I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement System Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemolytic-Uremic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heterozygote", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Homozygote", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Cofactor Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Purpura, Thrombotic Thrombocytopenic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service d'Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.414093.b", 
          "name": [
            "Service d'Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dragon-Durey", 
        "givenName": "Marie-Agn\u00e8s", 
        "id": "sg:person.0706660410.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706660410.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de M\u00e9decine, 75006, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Service d'Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France", 
            "INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de M\u00e9decine, 75006, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fr\u00e9meaux-Bacchi", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.0776460004.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776460004.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00862598", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000380400", 
          "https://doi.org/10.1007/bf00862598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-004-1526-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011641665", 
          "https://doi.org/10.1007/s00467-004-1526-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-09-28", 
    "datePublishedReg": "2005-09-28", 
    "description": "Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) disorder characterised by the association of haemolytic anaemia, thrombocytopenia and acute renal failure. Atypical forms (non-related to shigatoxin) may be familial or sporadic, with frequent recurrences and most of them lead to end stage renal failure. During the last years, different groups have demonstrated genetic predisposition of atypical HUS involving complement components factor H (FH), CD46 [or membrane co-factor protein (MCP)] and factor I. These three proteins are involved in the regulation of the alternative pathway of the complement system. Several series have reported mutations in the FH gene (called HF1) in between 10 and 22% of atypical HUS patients. At this time, four pedigrees corresponding to 13 cases have been reported with an MCP mutation and four cases with a sporadic disease presented factor I mutation. Whereas FH mutations were reported in both familial and sporadic forms of HUS, CD46 mutations were restricted to familial HUS, and factor I mutations were only observed in cases of sporadic HUS. We speculate that the penetrance of the disease may be variable regarding the identified susceptibility factors. Recently, the analysis of single nucleotide polymorphisms in both HF1 and MCP in three large cohorts of HUS patients identified significant association between atypical HUS and HF1 and MCP particular alleles. All these results, together with the finding of anti-FH antibodies in some atypical HUS patients, strongly suggest that an abnormality in the regulation of the alternative pathway participates in the patho-physiological mechanisms of atypical HUS. The recent progress made in the determination of susceptibility factors for atypical HUS has permitted the development of new diagnostic tests and may eventually lead to new specific treatments to block the pathological process.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00281-005-0003-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1038741", 
        "issn": [
          "1863-2297", 
          "1863-2300"
        ], 
        "name": "Seminars in Immunopathology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "atypical haemolytic uraemic syndrome", 
      "haemolytic uraemic syndrome", 
      "factor I mutation", 
      "atypical HUS patients", 
      "HUS patients", 
      "renal failure", 
      "uraemic syndrome", 
      "end-stage renal failure", 
      "susceptibility factors", 
      "acute renal failure", 
      "stage renal failure", 
      "patho-physiological mechanisms", 
      "factor H", 
      "sporadic haemolytic uraemic syndrome", 
      "anti-FH antibodies", 
      "new diagnostic tests", 
      "thrombotic microangiopathy disorders", 
      "new specific treatments", 
      "I mutations", 
      "MCP mutations", 
      "frequent recurrence", 
      "large cohort", 
      "genetic predisposition", 
      "specific treatment", 
      "haemolytic anaemia", 
      "CD46 mutation", 
      "sporadic forms", 
      "complement regulator genes", 
      "sporadic disease", 
      "significant association", 
      "FH mutations", 
      "atypical forms", 
      "complement system", 
      "FH gene", 
      "patients", 
      "diagnostic tests", 
      "alternative pathway", 
      "pathological processes", 
      "single nucleotide polymorphisms", 
      "syndrome", 
      "disease", 
      "nucleotide polymorphisms", 
      "factor I.", 
      "association", 
      "mutations", 
      "thrombocytopenia", 
      "failure", 
      "anemia", 
      "recurrence", 
      "cohort", 
      "particular alleles", 
      "pathway", 
      "abnormalities", 
      "different groups", 
      "cases", 
      "antibodies", 
      "CD46", 
      "disorders", 
      "predisposition", 
      "regulator gene", 
      "factors", 
      "treatment", 
      "genes", 
      "penetrance", 
      "regulation", 
      "last years", 
      "polymorphism", 
      "group", 
      "years", 
      "findings", 
      "alleles", 
      "protein", 
      "MCP", 
      "test", 
      "pedigree", 
      "mechanism", 
      "HF1", 
      "i.", 
      "recent progress", 
      "development", 
      "form", 
      "time", 
      "analysis", 
      "series", 
      "progress", 
      "results", 
      "determination", 
      "system", 
      "process"
    ], 
    "name": "Atypical haemolytic uraemic syndrome and mutations in complement regulator genes", 
    "pagination": "359-374", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034722638"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00281-005-0003-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16189652"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00281-005-0003-2", 
      "https://app.dimensions.ai/details/publication/pub.1034722638"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00281-005-0003-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'


 

This table displays all metadata directly associated to this object as RDF triples.

217 TRIPLES      21 PREDICATES      128 URIs      118 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00281-005-0003-2 schema:about N1530aeb96c6e430e9fb392610100c1f9
2 N298512d861364d5ea522603b03f1d65d
3 N45501ec33b5941d2bd4036ca3ebd8372
4 N54c557948c69455fa9f36e4f5d5610db
5 N554013fb969949c2b79eaa5d286abb84
6 N5935f5e3532041269497b8fc6630678c
7 N67d05e44d1344812ae47cd36296cf5f9
8 N795bfae95ad3472f8b27e26588824a3a
9 N950b8ac312db4e8b80613f4ef8814c26
10 Nc26c04443e684161842ff8b1360e7b64
11 Ndb73945a7bf14662a0090cf6fbf10288
12 Nfa5acab6049a41308ea1707f99621bff
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N83ddf92ba0ff447198512c303c60bb1e
16 schema:citation sg:pub.10.1007/bf00862598
17 sg:pub.10.1007/s00467-004-1526-9
18 schema:datePublished 2005-09-28
19 schema:datePublishedReg 2005-09-28
20 schema:description Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) disorder characterised by the association of haemolytic anaemia, thrombocytopenia and acute renal failure. Atypical forms (non-related to shigatoxin) may be familial or sporadic, with frequent recurrences and most of them lead to end stage renal failure. During the last years, different groups have demonstrated genetic predisposition of atypical HUS involving complement components factor H (FH), CD46 [or membrane co-factor protein (MCP)] and factor I. These three proteins are involved in the regulation of the alternative pathway of the complement system. Several series have reported mutations in the FH gene (called HF1) in between 10 and 22% of atypical HUS patients. At this time, four pedigrees corresponding to 13 cases have been reported with an MCP mutation and four cases with a sporadic disease presented factor I mutation. Whereas FH mutations were reported in both familial and sporadic forms of HUS, CD46 mutations were restricted to familial HUS, and factor I mutations were only observed in cases of sporadic HUS. We speculate that the penetrance of the disease may be variable regarding the identified susceptibility factors. Recently, the analysis of single nucleotide polymorphisms in both HF1 and MCP in three large cohorts of HUS patients identified significant association between atypical HUS and HF1 and MCP particular alleles. All these results, together with the finding of anti-FH antibodies in some atypical HUS patients, strongly suggest that an abnormality in the regulation of the alternative pathway participates in the patho-physiological mechanisms of atypical HUS. The recent progress made in the determination of susceptibility factors for atypical HUS has permitted the development of new diagnostic tests and may eventually lead to new specific treatments to block the pathological process.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N08f96a25850043a8a71d9e59f6cc3ed2
24 N8ed36e5b765342d2bc1b5ef9a1e634d6
25 sg:journal.1038741
26 schema:keywords CD46
27 CD46 mutation
28 FH gene
29 FH mutations
30 HF1
31 HUS patients
32 I mutations
33 MCP
34 MCP mutations
35 abnormalities
36 acute renal failure
37 alleles
38 alternative pathway
39 analysis
40 anemia
41 anti-FH antibodies
42 antibodies
43 association
44 atypical HUS patients
45 atypical forms
46 atypical haemolytic uraemic syndrome
47 cases
48 cohort
49 complement regulator genes
50 complement system
51 determination
52 development
53 diagnostic tests
54 different groups
55 disease
56 disorders
57 end-stage renal failure
58 factor H
59 factor I mutation
60 factor I.
61 factors
62 failure
63 findings
64 form
65 frequent recurrence
66 genes
67 genetic predisposition
68 group
69 haemolytic anaemia
70 haemolytic uraemic syndrome
71 i.
72 large cohort
73 last years
74 mechanism
75 mutations
76 new diagnostic tests
77 new specific treatments
78 nucleotide polymorphisms
79 particular alleles
80 patho-physiological mechanisms
81 pathological processes
82 pathway
83 patients
84 pedigree
85 penetrance
86 polymorphism
87 predisposition
88 process
89 progress
90 protein
91 recent progress
92 recurrence
93 regulation
94 regulator gene
95 renal failure
96 results
97 series
98 significant association
99 single nucleotide polymorphisms
100 specific treatment
101 sporadic disease
102 sporadic forms
103 sporadic haemolytic uraemic syndrome
104 stage renal failure
105 susceptibility factors
106 syndrome
107 system
108 test
109 thrombocytopenia
110 thrombotic microangiopathy disorders
111 time
112 treatment
113 uraemic syndrome
114 years
115 schema:name Atypical haemolytic uraemic syndrome and mutations in complement regulator genes
116 schema:pagination 359-374
117 schema:productId N015656375f8249b28832a02342fe55ba
118 N70adab61e7774711a2ba77bc1fa67b09
119 Ncf267b25dc9c4b2a81eb90d22fdb59ba
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034722638
121 https://doi.org/10.1007/s00281-005-0003-2
122 schema:sdDatePublished 2022-08-04T16:55
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher Na43e802fb7e74752b9b60c3b64b06d9b
125 schema:url https://doi.org/10.1007/s00281-005-0003-2
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N015656375f8249b28832a02342fe55ba schema:name pubmed_id
130 schema:value 16189652
131 rdf:type schema:PropertyValue
132 N08f96a25850043a8a71d9e59f6cc3ed2 schema:issueNumber 3
133 rdf:type schema:PublicationIssue
134 N1530aeb96c6e430e9fb392610100c1f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Membrane Cofactor Protein
136 rdf:type schema:DefinedTerm
137 N298512d861364d5ea522603b03f1d65d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Heterozygote
139 rdf:type schema:DefinedTerm
140 N45501ec33b5941d2bd4036ca3ebd8372 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Hemolytic-Uremic Syndrome
142 rdf:type schema:DefinedTerm
143 N54c557948c69455fa9f36e4f5d5610db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N554013fb969949c2b79eaa5d286abb84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Mutation
148 rdf:type schema:DefinedTerm
149 N5935f5e3532041269497b8fc6630678c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Complement Factor H
151 rdf:type schema:DefinedTerm
152 N6144bbe23fc3479990513bbbf4db63e1 rdf:first sg:person.0776460004.20
153 rdf:rest rdf:nil
154 N67d05e44d1344812ae47cd36296cf5f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Models, Immunological
156 rdf:type schema:DefinedTerm
157 N70adab61e7774711a2ba77bc1fa67b09 schema:name doi
158 schema:value 10.1007/s00281-005-0003-2
159 rdf:type schema:PropertyValue
160 N795bfae95ad3472f8b27e26588824a3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Homozygote
162 rdf:type schema:DefinedTerm
163 N83ddf92ba0ff447198512c303c60bb1e rdf:first sg:person.0706660410.14
164 rdf:rest N6144bbe23fc3479990513bbbf4db63e1
165 N8ed36e5b765342d2bc1b5ef9a1e634d6 schema:volumeNumber 27
166 rdf:type schema:PublicationVolume
167 N950b8ac312db4e8b80613f4ef8814c26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Purpura, Thrombotic Thrombocytopenic
169 rdf:type schema:DefinedTerm
170 Na43e802fb7e74752b9b60c3b64b06d9b schema:name Springer Nature - SN SciGraph project
171 rdf:type schema:Organization
172 Nc26c04443e684161842ff8b1360e7b64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Complement System Proteins
174 rdf:type schema:DefinedTerm
175 Ncf267b25dc9c4b2a81eb90d22fdb59ba schema:name dimensions_id
176 schema:value pub.1034722638
177 rdf:type schema:PropertyValue
178 Ndb73945a7bf14662a0090cf6fbf10288 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Complement Factor I
180 rdf:type schema:DefinedTerm
181 Nfa5acab6049a41308ea1707f99621bff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Autoantibodies
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1038741 schema:issn 1863-2297
191 1863-2300
192 schema:name Seminars in Immunopathology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.0706660410.14 schema:affiliation grid-institutes:grid.414093.b
196 schema:familyName Dragon-Durey
197 schema:givenName Marie-Agnès
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706660410.14
199 rdf:type schema:Person
200 sg:person.0776460004.20 schema:affiliation grid-institutes:grid.7429.8
201 schema:familyName Frémeaux-Bacchi
202 schema:givenName Véronique
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776460004.20
204 rdf:type schema:Person
205 sg:pub.10.1007/bf00862598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000380400
206 https://doi.org/10.1007/bf00862598
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s00467-004-1526-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011641665
209 https://doi.org/10.1007/s00467-004-1526-9
210 rdf:type schema:CreativeWork
211 grid-institutes:grid.414093.b schema:alternateName Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France
212 schema:name Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France
213 rdf:type schema:Organization
214 grid-institutes:grid.7429.8 schema:alternateName INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de Médecine, 75006, Paris, France
215 schema:name INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de Médecine, 75006, Paris, France
216 Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France
217 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...